Diasorin S.p.a. · MIL:DIA
Diasorin — Q1 2020 Earnings Presentation
13 slides from Diasorin's earnings presentation, May 13, 2020
Slide 1: Q1 2020 Results
Q1 2020 RESULTS eA ee) DiaSorin
Slide 2: Disclaimer
Disclaimer These statements are related, among others, to the intent, belief or current expectations of the customer base, estimates regarding future growth in the different business lines and the global business, market share, financial results and other aspects of the activities and situation rela
Slide 3: Highlights
Highlights Q1 2020 LIAISON CLIA PLACEMENTS Value in €/mln @ curr @ CER Q1 2020 @ MAR 31, 2020 REVENUES 174.6 +2.3% +1.7% Installed base +94 8,383 CLIA EX VIT D +2.8% +2.8% VIT D -12.7% -13.8% ELISA TESTS -9.2% -9.8% MOLECULAR TESTS PRODUCT DEVELOPMENT +51.4% +47.9% INSTRUMENTS & OTHER REVENUES -6.6%
Slide 4: Q1 2020 revenue growth
Q1 2020 revenue growth Q1’20 vs. Q1’19 Q1'20 vs. Q1'19 (*) Deep dive on Covid-19 impact on geographies @ curr +2.3% EUROPE & AFRICA +9.0% Total Group revenues @ CER +1.7% • 2 opposite dynamics in the period: Italy +0.5% Key impacting factors: 1. Routine tests volume slowdown in areas affected by Cov
Slide 5: Q1 2020 revenues breakdown @ current exchange rate
Q1 2020 revenues breakdown @ current exchange rate BY GEOGRAPHY BY TECHNOLOGY Instruments & other revenues 10.4% Q1’19 U.S. & Canada Q1'19 28.6% Molecular diagnostic Europe & tests Africa CLIA 9.5% 48.0% tests ELISA 66.6% Asia tests Pacific 13.5% Latin America 17.9% 5.5% Instruments & other revenues
Slide 6: Q1 2020 profitability profile
Q1 2020 profitability profile (€/mln) Q1'19 Q1'20 Change % Slight decrease in profitability (69.1% of revenues in Q1’20 vs. 69.5% GROSS PROFIT 118.6 120.7 +1.7% in Q1’19) due to different product & geography sales’ mix and to higher distribution costs, following the negative impact of Coronavirus on
Slide 7: Company Guidance
Company Guidance 7
Slide 8: Company Guidance
Company Guidance Company’s business outlook released on March 11, 2020 did not reflect the impacts deriving from COVID-19 and therefore cannot remain unchanged. Given the significant deterioration of the macroeconomic scenario and the related market uncertainties caused by the global spread of the p
Slide 9: Financial schemes
Financial schemes 9
Slide 10: Income Statement
Income Statement Q1 Change (Amounts in million of euros) 2019 2020 amount % Net Revenues 170.8 174.6 +3.9 +2.3% Cost of sales (52.1) (54.0) -1.8 +3.5% Gross profit 118.6 120.7 +2.0 +1.7% 69.5% 69.1% -0.4% Sales and marketing expenses (34.5) (36.4) -1.8 +5.2% Research and development costs (11.7) (12
Slide 11: Balance Sheet
Balance Sheet (Amounts in million of euros) 12/31/2019 03/31/2020 Change Goodwill and intangibles assets 370.3 377.4 +7.1 Property, plant and equipment 128.4 125.8 -2.6 Other non-current assets 34.1 35.5 +1.4 Net working capital 211.0 211.4 +0.4 Other non-current liabilities (68.0) (71.1) -3.1 Net I
Slide 12: Cash flow statement
Cash flow statement Q1 (Amounts in million of euros) 2019 2020 Cash and cash equivalents at the beginning of the period 73.1 157.6 Cash provided by operating activities 48.0 55.8 Cash used in investing activities (12.9) (16.0) Cash provided/(used) in financing activities (10.0) (0.7) Acquisitions of
Slide 13: DiaSorin
DiaSorin